Healthcare
Mesoblast Limited(MEOBF)
Live Price
Offline$1.55
+0.00% today
Window Change
-8.82%
Window
May 29, 2026 β Jun 23, 2026
- Market Cap
- $2.05B
- Revenue Growth
- +191.4%
- EPS Growth
- +3.6%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 17 bars Β· May 29, 2026 β Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Mesoblast Limited (MEOBF) is a Healthcare stock with a market cap of $2.05B and listed on OTC. The stock last traded around $1.55 and down 8.8% across the available one-year price window (May 29, 2026 β Jun 23, 2026). Baseline metrics include revenue growth of +191.4%, EPS growth of +3.6%, a dividend yield of 0.0%. What stands out right now is revenue +191.4%, EPS +3.6%, free cash flow -3.9% with operating margin -572.0% and ROIC -12.4%. Valuation already assumes a fairly strong business story at price/sales 131.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines MEOBF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+191.4% vs +7.6% peer median
Operating Margin
Below sector median
-572.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Feb 26, 2026 with an EPS surprise of -31.2% and a revenue surprise of -3.3%.
The operating story is still moving forward
Revenue is running at +191.4% and EPS at +3.6%, with operating margin around -572.0%.
The next real check-in already has a date
The next earnings event is scheduled for Sep 2, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Benchmark Edge
MEOBF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MEOBF
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MEOBF Max Drawdown
-8.82%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MEOBF and SPY.
Company Overview
Mesoblast Limited
Other OTC
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and GrΓΌnenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
- Leadership
- Silviu Itescu
- IPO Date
- Oct 15, 2010
- Employees
- 73
- Street Address
- 55 Collins Street
- Mailing
- Melbourne, VIC, 3000
- Region
- Melbourne, VIC, AU
- Reporting Currency
- USD
- Investor Line
- 61 3 9639 6036
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- 131.3
- Price/Book
- 3.5
Growth
- Revenue
- +191.4%
- EPS
- +3.6%
- Free Cash Flow
- -3.9%
Profitability
- Gross Margin
- -218.7%
- Operating Margin
- -572.0%
- Net Margin
- -500.5%
- ROE
- -14.0%
- ROIC
- -12.4%
Balance Sheet
- Debt/Equity
- 0.24
- Current Ratio
- 1.58
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.